Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 01 Mar 2022 for Poseida Therapeutics, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Matthew A. Spear: trading record in brief
This profile gathers the share dealings of Matthew A. Spear in Poseida Therapeutics, Inc., where the filings describe the role as senior executive. Between 11 June 2021 and 1 March 2022, the trades on record add up to 7 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 1 March 2022 came the latest disclosure, a share grant in Poseida Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Matthew A. Spear
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
50,000 shares0Common StockSEC:0001209191-22-014373:0
10,000 shares@ US$1.32219.6% of flowCommon StockSEC:0001209191-21-068629:0
10,000 shares@ US$1.32218.8% of flowCommon StockSEC:0001209191-21-055443:0
4,000 shares@ US$1.3227.6% of flowCommon StockSEC:0001209191-21-053177:0
20,000 shares@ US$1.32237.4% of flowCommon StockSEC:0001209191-21-048793:0
5,000 shares@ US$1.3229.3% of flowCommon StockSEC:0001209191-21-042292:0
4,000 shares@ US$1.3227.3% of flowCommon StockSEC:0001209191-21-040324:0
7 of 7 declarations
